INCB057643 (BET bromodomain inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-05 — The impact of novel bet inhibitors on the treatment armamentarium of Myelofibrosis.: Review-level synthesis on BET inhibitors in MF includes INCB057643 among the investigational class shown to modulate inflammatory/fibrotic/proliferative transcriptional programs, with hematologic toxicity flagged as a class-level safety concern. (novelty: 3)
- May 21, 20 — CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management: Review-level synthesis (May 2026) lists INCB057643 among BET inhibitor approaches being advanced in parallel with pelabresib (MANIFEST-3) as targeted combination strategies in MPN management. (novelty: 3)
- May 22, 20 — All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025: ASH 2025 conference review situates INCB057643 within the broader BET-inhibitor + ruxolitinib add-on landscape, alongside the positive 96-week MANIFEST-2 readout for pelabresib + ruxolitinib that validates BET inhibition as a frontline MF combination strategy. (novelty: 3)
- January 21 — Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis: cross-connection with zavabresib-bet-inhibitor-mpn: Both are BET bromodomain inhibitors being developed as ruxolitinib add-ons in MF; zavabresib is described as having a distinct selectivity profile from INCB057643. (novelty: 3)
- May 12, 20 — CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management: Review-level commentary highlights BET inhibition (INCB057643) among the emerging non-JAK targeted approaches being advanced alongside CALR-directed agents in MPN management. (novelty: 3)
- 2026-04-01 — Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms: Trial-early: Phase 1 safety/tolerability study evaluating INCB057643 as monotherapy and in combination with ruxolitinib in myelofibrosis and other advanced myeloid neoplasms; primary endpoints are safety and tolerability with preliminary efficacy as secondary. (novelty: 3)
Open questions
Related
Contributing findings
All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025
May 22, 2026
novelty 3
per-area 3
strengthens
CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management
May 21, 2026
novelty 3
per-area 2
mentions
CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management
May 12, 2026
novelty 3
per-area 3
mentions
The impact of novel bet inhibitors on the treatment armamentarium of Myelofibrosis.
05-jun-2026
novelty 3
per-area 3
strengthens
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
16-apr-2026
novelty 4
per-area 4
strengthens
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
02-apr-2026
novelty 3
per-area 3
strengthens
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
01-apr-2026
novelty 3
per-area 4
introduces
🔎 Auto-added searches
| Query | Source | Added | Hits | Rationale |
|---|---|---|---|---|
"INCB057643"[Title/Abstract] OR ("BET bromodomain inhibitor"[Title/Abstract] AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract])) |
pubmed | 31-may-2026 | 1 / 9 | Targets INCB057643 specifically and BET bromodomain inhibitors in MPN context, which no existing static or dynamic query covers. |
Show 1 demoted
| Query | Source | Demoted | Reason |
|---|---|---|---|
INCB057643 BET bromodomain inhibitor myelofibrosis |
biorxiv | 22-jun-2026 | (manual) biorxiv keyword-matching too loose (v1 OR/substring); expansion moved to pubmed-only |